Reviving Molecules With Minds: AI-Driven Drug Repurposing Through Case-Based Intelligence

Abstract

The drug discovery process is traditionally slow and expensive, with high rates of failure during clinical trials. However, artificial intelligence (AI) has transformed this landscape by accelerating the identification of existing drugs that can be repurposed for new therapeutic indications. This innovative approach, known as AI-driven drug repurposing, utilizes advanced machine learning (ML) algorithms and deep learning (DL) models to analyze large datasets, including genomic information, patient records, and clinical trial outcomes, to predict novel drug-disease relationships. One of the most striking examples of AI's potential is the repurposing of existing antiviral drugs like remdesivir and chloroquine for COVID-19. Through AI's ability to rapidly analyze vast molecular and clinical data, these drugs were identified as potential candidates to combat the global pandemic. In oncology, AI has facilitated the exploration of metformin and statins, repurposing them for cancer treatment based on their ability to target multiple pathways involved in tumor growth. Similarly, AI in neurology has identified new applications for drugs originally developed for other conditions, offering hope for neurodegenerative diseases like Alzheimer’s. While AI promises substantial benefits in drug development, challenges such as data quality, regulatory approval, and ethical concerns must be overcome. As AI models become more refined, the potential for drug repurposing will revolutionize healthcare, reducing development timelines and providing personalized therapeutic options for patients across a variety of diseases, from rare conditions to pandemics.